Literature DB >> 22128289

An overview of the c-MET signaling pathway.

Shawna Leslie Organ1, Ming-Sound Tsao.   

Abstract

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion. Although c-MET is important in the control of tissue homeostasis under normal physiological conditions, it has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression. This paper provides an overview of the c-MET signaling pathway, including its role in the development of cancers, and provides a rationale for targeting the pathway as a possible treatment option.

Entities:  

Keywords:  MET; c-MET; cancer; hepatocyte growth factor (HGF); receptor tyrosine kinase; signaling

Year:  2011        PMID: 22128289      PMCID: PMC3225017          DOI: 10.1177/1758834011422556

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  118 in total

1.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

Authors:  M Ivan; J A Bond; M Prat; P M Comoglio; D Wynford-Thomas
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

2.  Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers.

Authors:  S E Hiscox; M B Hallett; M C Puntis; T Nakamura; W G Jiang
Journal:  Cancer Invest       Date:  1997       Impact factor: 2.176

3.  Ron kinase transphosphorylation sustains MET oncogene addiction.

Authors:  Silvia Benvenuti; Luca Lazzari; Addolorata Arnesano; Giulia Li Chiavi; Alessandra Gentile; Paolo M Comoglio
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

4.  Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.

Authors:  Wataru Okamoto; Isamu Okamoto; Takeshi Yoshida; Kunio Okamoto; Ken Takezawa; Erina Hatashita; Yuki Yamada; Kiyoko Kuwata; Tokuzo Arao; Kazuyoshi Yanagihara; Masahiro Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

5.  Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

Authors:  M Olivero; G Valente; A Bardelli; P Longati; N Ferrero; C Cracco; C Terrone; S Rocca-Rossetti; P M Comoglio; M F Di Renzo
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

6.  Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein.

Authors:  E D Fixman; T M Fournier; D M Kamikura; M A Naujokas; M Park
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks.

Authors:  Dean E Hammond; Russell Hyde; Irina Kratchmarova; Robert J Beynon; Blagoy Blagoev; Michael J Clague
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

Review 8.  Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis.

Authors:  Hirokazu Okada; Raghu Kalluri
Journal:  Curr Mol Med       Date:  2005-08       Impact factor: 2.222

9.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

10.  HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Authors:  Hanane Khoury; Monica A Naujokas; Dongmei Zuo; Veena Sangwan; Melanie M Frigault; Stephanie Petkiewicz; David L Dankort; William J Muller; Morag Park
Journal:  Mol Biol Cell       Date:  2004-11-17       Impact factor: 4.138

View more
  260 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

2.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

Review 3.  C-MET inhibitors in the treatment of lung cancer.

Authors:  Joanna Goździk-Spychalska; Katarzyna Szyszka-Barth; Lukasz Spychalski; Katarzyna Ramlau; Jerzy Wójtowicz; Halina Batura-Gabryel; Rodryg Ramlau
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 4.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

Review 5.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

6.  MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.

Authors:  Jessica B Casaletto; Melissa L Geddie; Adnan O Abu-Yousif; Kristina Masson; Aaron Fulgham; Antoine Boudot; Tim Maiwald; Jeffrey D Kearns; Neeraj Kohli; Stephen Su; Maja Razlog; Andreas Raue; Ashish Kalra; Maria Håkansson; Derek T Logan; Martin Welin; Shrikanta Chattopadhyay; Brian D Harms; Ulrik B Nielsen; Birgit Schoeberl; Alexey A Lugovskoy; Gavin MacBeath
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-21       Impact factor: 11.205

7.  Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Biomed Rep       Date:  2014-09-10

8.  Combined Systemic Disruption of MET and Epidermal Growth Factor Receptor Signaling Causes Liver Failure in Normal Mice.

Authors:  Anastasia Tsagianni; Wendy M Mars; Bharat Bhushan; William C Bowen; Anne Orr; John Stoops; Shirish Paranjpe; George C Tseng; Silvia Liu; George K Michalopoulos
Journal:  Am J Pathol       Date:  2018-07-20       Impact factor: 4.307

Review 9.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

10.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.